Failure of pre-exposure prophylaxis with daily tenofovir/emtricitabine and the scenario of delayed HIV seroconversion.

Autor:	Lee SS; Stanley Ho Centre for Emerging Infectious Diseases, Chinese University of Hong Kong, Shatin, Hong Kong. Electronic address: sslee@cuhk.edu.hk., Anderson PL; Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, Colorado, USA., Kwan TH; Stanley Ho Centre for Emerging Infectious Diseases, Chinese University of Hong Kong, Shatin, Hong Kong., Lui GCY; Department of Medicine and Therapeutics, Chinese University of Hong Kong, Shatin, Hong Kong., Chan DPC; Stanley Ho Centre for Emerging Infectious Diseases, Chinese University of Hong Kong, Shatin, Hong Kong., Wong NS; Stanley Ho Centre for Emerging Infectious Diseases, Chinese University of Hong Kong, Shatin, Hong Kong., Lee KCK; Stanley Ho Centre for Emerging Infectious Diseases, Chinese University of Hong Kong, Shatin, Hong Kong., Lam TTN; School of Pharmacy, Chinese University of Hong Kong, Shatin, Hong Kong.
Jazyk:	angličtina
Zdroj:	International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases [Int J Infect Dis] 2020 May; Vol. 94, pp. 41-43. Date of Electronic Publication: 2020 Mar 13.
DOI:	10.1016/j.ijid.2020.03.014
Abstrakt:	Failure of pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine may occur despite perfect adherence, although this is uncommon. Failure results in breakthrough HIV infection. Delayed seroconversion associated with antiretroviral use may complicate the picture, causing uncertainties in interpreting adherence patterns for establishing the true cause of PrEP failure. (Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu